AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema

RecruitingNAAges 18 Years - 75 YearsAllUniversity Hospital, Toulouse
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Patients in who developed primary lymphedema or secondary lymphedema after breast cancer treatment. 2. Male and female over the age of 18 and under 75. 3. Patient affiliated to a social security scheme in France. 4. Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study. 5. Patients with no recidive \> 3 years after cancer surgery. 6. Patients with Body Mass Index \<35. 7. Patient enrolled in a care pathway for the management of their lymphedema (medical and educational care). 8. Patients wearing a compression orthosis on the limb with lymphedema. Exclusion Criteria: 1. Patients with strong suspicion or with active bacterial or fungal infection. 2. Patient with venous insufficiency associated with lymphedema. 3. Patient with a history of deep venous thrombosis on the limb with lymphedema. 4. History of chronic inflammatory disease. 5. Active neoplasia during parallel management. 6. Patient already included in another therapeutic trial. 7. Pregnant or breastfeeding woman. 8. Metastatic cancer. 9. Bilateral breast cancer. 10. Obliterative arterial disease. 11. Multiple erysipelas. 12. Active smoking (delayed healing). 13. Medicines that may promote delayed healing (Corticosteroid therapy, immunosuppressants). 14. Medication that thins the blood (aspirin and antiplatelet agent, anti-coagulant). 15. Betadine allergy. 16. Patient under guardianship or trusteeship, persons placed under the protection of justice
๐Ÿ’Š

What it tests

  • Micro-biopsies
๐Ÿ“

Where

1 site
Toulouse Hospital
Toulouse, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy